New Test to Predict Primary Melanoma Progression
21 January 2020
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.
The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.
The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.
‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.
‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.
Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.
While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.
Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.
‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’
Dr James Wilmott awarded for outstanding cancer research
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
Community invests in MIA's new trial
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
New trial giving options
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Melanoma research summary from ASCO
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
Updated privacy policy
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Can cognitive technology assist with melanoma identification?
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
'4 Questions With...' Series
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
Stop the Spread campaign shortlisted
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
A meeting of the minds
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
MIA's Dermatology services expanded
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
5 Minutes with Maria Gonzalez
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
Melanoma eBook to educate GPs
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
5 Minutes with Dr Scot Ebbinghaus
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
Opdivo available on PBS for advanced melanoma patients
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
5 Minutes with Dr Louise Jackett
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA patient's plight highlighted in ABC series
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Recruiting: Pregnancy and moles study
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
The role of radiotherapy in melanoma
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
Australian melanoma rates take the silver – and that's good news
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.